Regencell Bioscience Holdings Limited (RGC) Balance Sheet

The balance sheet has moved through a clear cycle, contracting from $21.1M of assets in 2022Q2 to a near-negative equity position of -$4.0M by 2021Q4 and then rebuilding sharply in the latest periods. The rebuilding pattern suggests the company has relied on capital raises to fund losses, and the widening retained deficit from -$11.4M in 2022Q4 to -$36.9M in 2026Q4 indicates that asset growth is not coming from retained operating profit. Investors should monitor whether future equity raises continue to be needed to sustain the cost base.

The current ratio of 10.77 and near-zero debt of $295.8K suggest short-term obligations are well covered by reported liquid assets. However, a cash balance of $14.2M against a quarterly operating burn of roughly $5.1M implies a runway of under three quarters at the latest pace, a figure that may indicate further financing will be required. The 2024Q4 position, with cash of $3.0M, shows how quickly the buffer has been depleted in prior cycles.

Debt has been negligible across most of the reported history, with peak borrowings of $771.3K in 2022Q4 falling to modest levels since. Low leverage means the balance sheet risk is driven by equity burn and cash runway rather than debt service. The absence of meaningful debt also reduces refinancing pressure, though it does not offset the operating losses that the rest of the statements show.

The asset mix is dominated by cash, with fixed assets remaining small relative to the total and no goodwill or intangible balance to create impairment exposure. This profile suggests limited capital intensity, consistent with the minimal capital expenditure in the cash flow statement. The main asset-quality question is therefore whether the cash balance can be converted into a productive revenue base before it is consumed by overhead.